Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 167

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration

Open access
Bakri, Sophie J., Thorne, Jennifer E., Ho, Allen C., Ehlers, Justis P., Schoenberger, Scott D., Yeh, Steven, Kim, Stephen J. · 2019 · Ophthalmology

Abstract

PURPOSE To review the evidence on the safety and efficacy of anti-vascular endothelial growth factor (VEGF) therapies for the treatment of neovascular age-related macular degeneration (AMD). METHODS A literature search of the PubMed and Cochrane Library databases was last conducted in February 2017; there were no date restrictions, and the search was limited to studies published in English. The combined searches yielded 191 citations, 28 of which were selected because they were clinical trials and were deemed clinically relevant for the Ophthalmic Technology Assessment Committee Retina/Vitreous Panel to review in full. The panel methodologist then assigned a level of evidence rating to each study. RESULTS Sixteen of the 28 citations provided level I evidence supporting the use of anti-VEGF agents for neovascular AMD, including intravitreal ranibizumab, aflibercept, and bevacizumab. Eight studies reviewed provided level II evidence, and 4 studies provided level III evidence, but only the level I studies are included in this assessment. There are long-term follow-up data on the efficacy of ranibizumab and bevacizumab (≥5 years), but these data are subject to the bias of incomplete follow-up. CONCLUSIONS Review of the literature indicates that intravitreal injection of anti-VEGF therapy is safe and effective for neovascular AMD over 2 years, the period for which data are available. Further research is needed to evaluate the long-term safety and comparative efficacy of these agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ophtha.2018.07.028

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 25

  1. Klein, 2011, Prevalence of age-related macular degeneration in the US population, Arch Ophthalmol, 129, 75, 10.1001/archophthalmol.2010.318 · DOI · Paper page
  2. Klein, 2013, The prevalence of age-related eye diseases and visual impairment in aging: current estimates, Invest Ophthalmol Vis Sci, 54, ORSF5, 10.1167/iovs.13-12789 · DOI · Paper page
  3. Lopez, 1996, Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes, Invest Ophthalmol Vis Sci, 37, 855
  4. Kvanta, 1996, Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor, Invest Ophthalmol Vis Sci, 37, 1929
  5. 1991, Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials, Arch Ophthalmol, 109, 1109, 10.1001/archopht.1991.01080080069030 · DOI · Paper page
  6. 1994, Laser photocoagulation for juxtafoveal choroidal neovascularization: five-year results from randomized clinical trials, Arch Ophthalmol, 112, 500, 10.1001/archopht.1994.01090160076025 · DOI · Paper page
  7. 1999, Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report, Arch Ophthalmol, 117, 1329, 10.1001/archopht.117.10.1329 · DOI · Paper page
  8. Ferrara, 2006, Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration, Retina, 26, 859, 10.1097/01.iae.0000242842.14624.e7 · DOI · Paper page
  9. Lee, 2005, A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165, Proc Natl Acad Sci U S A, 102, 18902, 10.1073/pnas.0509069102 · DOI · Paper page
  10. Chakravarthy, 2012, Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial, Ophthalmology, 119, 1399, 10.1016/j.ophtha.2012.04.015 · DOI · Paper page
  11. Kodjikian, 2013, Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial, Ophthalmology, 120, 2300, 10.1016/j.ophtha.2013.06.020 · DOI · Paper page
  12. Antoszyk, 2008, Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results, Am J Ophthalmol, 145, 862, 10.1016/j.ajo.2007.12.029 · DOI · Paper page
  13. Silva, 2013, The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration, Ophthalmology, 120, 130, 10.1016/j.ophtha.2012.07.026 · DOI
  14. Chakravarthy, 2006, Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration, Ophthalmology, 113, 1508.e1
  15. Meredith, 2015, Postinjection endophthalmitis in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), Ophthalmology, 122, 817, 10.1016/j.ophtha.2014.10.027 · DOI
  16. Bakri, 2014, Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials, Ophthalmology, 121, 1102, 10.1016/j.ophtha.2013.11.029 · DOI
  17. Dedania, 2015, Sustained elevation of intraocular pressure after intravitreal anti-vegf agents: what is the evidence?, Retina, 35, 841, 10.1097/IAE.0000000000000520 · DOI
  18. Bakri, 2009, Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab, Eye (Lond), 23, 181, 10.1038/sj.eye.6702938 · DOI · Paper page
  19. Bressler, 2012, Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials, Retina, 32, 1821, 10.1097/IAE.0b013e31825db6ba · DOI
  20. Kodjikian, 2014, Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials, Graefes Arch Clin Exp Ophthalmol, 252, 1529, 10.1007/s00417-014-2764-6 · DOI
  21. Finger, 2014, The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration, Ophthalmology, 121, 1246, 10.1016/j.ophtha.2013.12.032 · DOI
  22. Mitchell, 2011, Cost effectiveness of treatments for wet age-related macular degeneration, PharmacoEconomics, 29, 107, 10.2165/11585520-000000000-00000 · DOI
  23. Patel, 2012, Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model, J Eval Clin Pract, 18, 247, 10.1111/j.1365-2753.2010.01546.x · DOI
  24. Stein, 2014, Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration, Ophthalmology, 121, 936, 10.1016/j.ophtha.2013.10.037 · DOI
  25. Nwanze, 2012, Bevacizumab vs. ranibizumab in preserving or improving vision in patients with wet, age-related macular degeneration: a cost-effectiveness review, Clin Med Insights Ther, 4, 29

Cited by

See all 167

Metadata

Authors
Bakri, S. J., Thorne, J. E., Ho, A. C., Ehlers, J. P., Schoenberger, S. D., Yeh, S., & Kim, S. J.
Venue
Ophthalmology
Publisher
Elsevier BV
Published
2019-01
Volume
126
Issue
1
Pages
55-63
ISSN
0161-6420 (ISSN-L)
OpenAlex
W2887429619
Cited by
167
References
18
FWCI
14.68
Type
journal article
Language
en
Update notices
erratum (2019-06-01)
Open access
bronze
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
American Academy of Ophthalmology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration. https://app.cochat.ai/papers/10.1016/j.ophtha.2018.07.028
The paper
Bakri, S. J., Thorne, J. E., Ho, A. C., Ehlers, J. P., Schoenberger, S. D., Yeh, S., & Kim, S. J. (2019). Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration. Ophthalmology. https://doi.org/10.1016/j.ophtha.2018.07.028

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.